期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 769, 期 -, 页码 266-273出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2015.11.028
关键词
Aldosterone; CS-3150; Mineralocorticoid receptor antagonist; Salt-sensitive hypertension; Renal injury
The present study was designed to evaluate the antihypertensive and cardiorenal protective effects of CS3150, a novel non-steroidal mineralocorticoid receptor antagonist, in Dahl salt-sensitive hypertensive rats (DS rats), and to compare the effects with spironolactone and eplerenone. DS rats were fed a control diet (0.3% NaCI) or high salt diet (8% NaCI) from 7 weeks of age. CS-3150 (0.25-2 mg/kg), spironolactone (10-100 mg/kg) or eplerenone (10-100 mg/kg) were orally administered once a day to DS rats fed a high salt diet for 7 weeks. The high salt diet significantly increased systolic blood pressure, which was prevented by treatment with CS-3150 in a dose-dependent manner with no hyperkalemia ( > 5.5 mEq/L). The antihypertensive effect of CS-3150 (0.5 mg/kg) was equivalent to that of spironolactone (100 mg/kg) and eplerenone (100 mg/kg). CS-3150 also suppressed proteinuria and renal hypertrophy induced by the high salt diet. Histopathological examination of kidneys showed that CS-3150 markedly ameliorated glomerulosclerosis, tubular injury and tubulointerstitial fibrosis. In addition, CS-3150 inhibited left ventricular hypertrophy and elevation of plasma brain natriuretic peptide level. In contrast, the cardiorenal protective effects of spironolactone or eplerenone were partial, and the dose-dependency was not clear, especially in eplerenone-treated rats. These results indicate that chronic treatment with CS-3150 exerts antihypertensive and cardiorenal protective effects in a DS hypertensive rat model, and its potency is much superior to that of spironolactone or eplerenone. Thus, CS-3150 could be a promising agent for the treatment of hypertension and cardiorenal disorders. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据